Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice

This publication has 28 references indexed in Scilit:

• Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years
  Journal of Urology, 1994
• Identification of bone marrow micrometastases in patients with prostate cancer
  Cancer, 1994
• Inhibitory effects of analogs of luteinizing hormone‐releasing hormone on the growth of the androgen‐independent dunning R‐3327‐AT‐1 rat prostate cancer
  International Journal of Cancer, 1994
• Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
  Proceedings of the National Academy of Sciences, 1994
• Characterization of high‐affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC‐3 and DU‐145: Internalization of receptor bound ¹²⁵I‐(Tyr⁴) bombesin by tumor cells
  The Prostate, 1994
• Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer
  Biomedicine & Pharmacotherapy, 1992
• Interactions between epidermal growth factor-mediated autocrine regulation and linoleic acid-stimulated growth of a human prostate cancer cell line
  The Prostate, 1992
• Bombesin stimulates growth of human prostatic cancer cellsin vitro
  Cancer, 1990
• Clinical Study of Leuprolide Depot Formulation in the Treatment of Advanced Prostate Cancer
  Journal of Urology, 1990
• Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate
  The Prostate, 1989